arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Eloxx Pharmaceuticals, Inc.

ELOX
$17.88 ▲ +0.42 (+2.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Eloxx Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $862.0M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC 39.5%
FCF / Share $-0.11
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.79M
↑ +12.6%
Net Income Profit after all expenses
$-3.75M
↓ -119.7%
FCF / Share Free cash flow per share
$-0.11
↓ -135.8%
Long-Term Debt Long-term obligations
$1.00M
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
98
Financial Health
63
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 27 years · 67 quarters